Agendia, Inc.

166 articles about Agendia, Inc.

• Agendia BV’s MammaPrint Now Included In First Coast Coverage For Medicare Breast Cancer Patients In Florida, Puerto Rico And The Virgin Islands

  5/2/2017

• Agendia BV Appoints Patrick J. Balthrop Sr., Former CEO Of Luminex, As Chairman

  4/20/2017

• Agendia BV Appoints Patrick J. Balthrop Sr., Former CEO Of Luminex, As Chairman

  4/13/2017

• European Group On Tumour Markers (EGTM) Updated Guidelines Recommend Agendia BV's Mammaprint Test With Highest Level 1A Clinical Evidence

  3/22/2017

• European Group On Tumour Markers (EGTM) Updated Guidelines Recommend Agendia BV’s Mammaprint Test With Highest Level 1A Clinical Evidence

  3/21/2017

• Agendia BV Release: German Community Of Gynecological Oncology (AGO) Acknowledges Mammaprint In Breast Cancer Guidelines As Having Level 1A Clinical Evidence

  3/8/2017

• Agendia BV Co-Founder Laura van ’t Veer Wins European Cancer Organization Clinical Research Award

  1/30/2017

• Agendia BV Release: New Data Shows That MammaPrint Substantially Impacts How Breast Cancer Patients In Germany Are Treated

  12/20/2016

• Agendia BV Release: Three New Studies Presented At San Antonio Breast Cancer Symposium Further Demonstrate Value Of Mammaprint And Blueprint In Individualizing Treatment For Breast Cancer Patients

  12/14/2016

• Agendia BV’s Mammaprint And Blueprint Tests Highlighted In Multiple Presentations At The 2016 San Antonio Breast Cancer Symposium, Adding Further Clinical Utility

  12/2/2016

• Agendia BV's Proven Breast Cancer Recurrence Assay, MammaPrint, Now Available In The Middle East

  11/8/2016

• Agendia BV Announces The Award Of A New Category 1 CPT Code From American Medical Association For The Mammaprint 70-Gene Breast Cancer Recurrence Assay

  11/2/2016

• Agendia BV Expands Its Business Activities In Germany

  10/26/2016

• Agendia BV Appoints Three Leading Cancer Physicians To Its Medical Advisory Board

  10/17/2016

• Agendia BV Release: The New England Journal of Medicine Publishes MINDACT Trial Results Proving The Clinical Utility Of Mammaprint In Assisting Physicians To Identify Early-Stage Breast Cancer Patients Who Can Safely Forgo Chemotherapy

  8/25/2016

• Agendia BV’s Mammaprint First And Only Genomic Assay To Receive Level 1A Clinical Utility Evidence For Chemotherapy Benefit In Early Breast Cancer Patients

  4/19/2016

• Agendia BV To Highlight New MammaPrint Data At The 2016 European Breast Cancer Conference As A Prelude To Upcoming MINDACT Trial Findings

  3/8/2016

• Agendia BV And Partners Receive $6.8 Million From European Commission (EC) To Study Targeted Therapies For Colorectal Cancer

  12/16/2015

• Agendia BV Highlights Study Showing MammaPrint/BluePrint Tests Predict Response To Current Breast Cancer Chemotherapy And Targeted Therapy Regimens

  9/29/2015

• Agendia BV Release: NCCN Breast Cancer Guidelines Acknowledge MammaPrint’s Ability to Predict Prognosis

  7/28/2015